Nature reviews drug discovery文章索引

期刊目录筛选

期刊名：Nature reviews drug discovery

缩写：NAT REV DRUG DISCOV

ISSN：1474-1776

e-ISSN：1474-1784

IF/分区：91.2/Q1

文章目录更多期刊信息

共收录本刊相关文章索引4154条

FDA approves GLP-1 pill for obesity [0.03%] 美国食品和药物管理局批准用于治疗肥胖的GLP-1片剂

Asher Mullard Asher Mullard

Nature reviews. Drug discovery. 2026 Apr 2. DOI:10.1038/d41573-026-00059-9 2026

Dialling up the circadian clock to target ageing [0.03%] 拨动昼夜钟以针对衰老问题施策

M Teresa Villanueva M Teresa Villanueva

Nature reviews. Drug discovery. 2026 Apr 2. DOI:10.1038/d41573-026-00057-x 2026

The expanding role of formulations to enable oral delivery of poorly water-soluble drugs [0.03%] 日益增长的口服制剂研发以实现难溶性药物的递送

Keisuke Ueda,Christopher J H Porter,Aaron Goodwin et al. Keisuke Ueda et al.

Contemporary small-molecule drug candidates increasingly have limited aqueous solubility, rendering oral delivery challenging. Amorphous solid dispersions (ASDs) and lipid-based formulations (LBFs) have evolved as leading formulation approa...

Review Nature reviews. Drug discovery. 2026 Apr 2. DOI:10.1038/s41573-026-01407-5 2026

A renaissance in targeting the PI3K/AKT/mTOR pathway [0.03%] PI3K/AKT/mTOR信号通路的靶向治疗迎来复兴

Sarah E Conduit,Neil Vasan,Jennifer R Brown et al. Sarah E Conduit et al.

The PI3K/AKT/mTOR pathway represents an excellent drug target, given its proven druggability and roles in cancer, immune regulation and genetic disorders. However, although some agents targeting this pathway have gained approval, drug devel...

Review Nature reviews. Drug discovery. 2026 Mar 30. DOI:10.1038/s41573-026-01388-5 2026

ROCK2 is a druggable angiocrine target in liver fibrosis [0.03%] ROCK2是肝纤维化治疗的可药用血管生成内分泌靶点

Isobel Leake Isobel Leake

Nature reviews. Drug discovery. 2026 Mar 30. DOI:10.1038/d41573-026-00053-1 2026

First-in-class blood-brain barrier shuttle wins FDA nod for Hunter syndrome [0.03%] 治疗亨特综合征的首款跨血脑屏障运输工具获得FDA批准

Asher Mullard Asher Mullard

Nature reviews. Drug discovery. 2026 Mar 27. DOI:10.1038/d41573-026-00055-z 2026

Oral macrocyclic IL-23 inhibitor nabs FDA approval for psoriasis [0.03%] 口服麦角环素类IL-23抑制剂获FDA批准治疗银屑病

Asher Mullard Asher Mullard

Nature reviews. Drug discovery. 2026 Mar 26. DOI:10.1038/d41573-026-00054-0 2026

Can a first disease-modifying osteoarthritis drug make it past the FDA? [0.03%] 首个治标又治本的抗骨关节炎药物能通过美国食品药品监督管理局审批吗？

Ken Garber Ken Garber

Nature reviews. Drug discovery. 2026 Mar 23. DOI:10.1038/d41573-026-00047-z 2026

Trikines rewire STAT signalling [0.03%] TRIKs重塑STAT信号转导

Sarah Crunkhorn Sarah Crunkhorn

Nature reviews. Drug discovery. 2026 Mar 23. DOI:10.1038/d41573-026-00052-2 2026

Targeted degradation of amyloid-β [0.03%] 靶向降解淀粉样蛋白-β

Sarah Crunkhorn Sarah Crunkhorn

Nature reviews. Drug discovery. 2026 Mar 23. DOI:10.1038/d41573-026-00051-3 2026